US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atea Pharmaceuticals, Inc.

2.88

+0.03001.05%

Volume:245.18K

Turnover:700.90K

Market Cap:246.31M

PE:-1.44

High:2.92

Open:2.82

Low:2.77

Close:2.85

Loading ...

Overview Company News Filings

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

THOMSON REUTERS

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

BUZZ-Atea Pharma rises as combo drug meets main goal in mid-stage study

Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir

Atea Pharmaceuticals Inc: Global Phase 3 Program Initiation Expected Early in 2025

THOMSON REUTERS

Atea Pharmaceuticals Inc - Phase 2 Study Achieves 98% Svr12 After 8 Weeks

THOMSON REUTERS

Atea Pharmaceuticals Inc - No Drug-Related Serious Adverse Events or Treatment Discontinuations

THOMSON REUTERS

Atea Pharmaceuticals Announces Positive Results From Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (Hcv)

THOMSON REUTERS

Atea Pharmaceuticals Inc - Regimen Generally Safe and Well-Tolerated

THOMSON REUTERS

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Atea Pharmaceuticals to Present and Provide a Business Update at the 7TH Annual Evercore Healthconx Conference

THOMSON REUTERS

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Atea Pharmaceuticals presents three HCV poster presentations at AASLD

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at Aasld’s the Liver Meeting 2024

THOMSON REUTERS

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

Atea Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

BRIEF-Atea Pharmaceuticals Inc Files For Mixed Shelf Of Up To $500 Million - SEC Filing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVIR/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVIR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVIR\",,,,,undefined,":{"symbol":"AVIR","market":"US","secType":"STK","nameCN":"Atea Pharmaceuticals, Inc.","latestPrice":2.88,"timestamp":1743624000000,"preClose":2.85,"halted":0,"volume":245183,"delay":0,"floatShares":66621403,"shares":85525179,"eps":-1.998285,"marketStatus":"Pre-Market Trading","change":0.03,"latestTime":"04-03 06:16:05 EDT","open":2.82,"high":2.92,"low":2.77,"amount":700896.1832864999,"amplitude":0.052632,"askPrice":2.88,"askSize":100,"bidPrice":1.21,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.998285,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743687000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1604030400000,"exchange":"NASDAQ","adjPreClose":2.88,"postHourTrading":{"tag":"盘后","latestPrice":2.88,"preClose":2.88,"latestTime":"18:17 EDT","volume":6768,"amount":19489.62,"timestamp":1743632255305},"volumeRatio":0.8695049294584547,"impliedVol":1.6849,"impliedVolPercentile":0.632},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVIR\",,,,,undefined,":{"symbol":"AVIR","floatShares":66621403,"roa":"-15.60%","roe":"-33.88%","lyrEps":-1.998285,"volumeRatio":0.8695049294584547,"shares":85525179,"dividePrice":0,"high":2.92,"amplitude":0.052632,"preClose":2.85,"low":2.77,"week52Low":2.75,"pbRate":"0.56","psRate":"1.28","week52High":4.145,"institutionHeld":0.4276,"latestPrice":2.88,"committee":0.333333,"eps":-1.998285,"divideRate":0,"volume":245183,"delay":0,"ttmEps":-1.998285,"open":2.82,"prevYearClose":3.35,"prevWeekClose":2.93,"prevMonthClose":2.99,"prevQuarterClose":2.99,"fiveDayClose":3.18,"twentyDayClose":3.01,"sixtyDayClose":3.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVIR\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2491686166","title":"Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2491686166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491686166?lang=en_us&edition=fundamental","pubTime":"2024-12-16 18:00","pubTimestamp":1734343206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NF02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVIR","BK4007"],"gpt_icon":0},{"id":"2491668194","title":"Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2491668194","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491668194?lang=en_us&edition=fundamental","pubTime":"2024-12-16 18:00","pubTimestamp":1734343200,"startTime":"0","endTime":"0","summary":"BOSTON, Dec.  16, 2024  (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ant","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997278/0/en/Atea-Pharmaceuticals-Retains-Financial-Advisor-to-Explore-Strategic-Partnerships.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR"],"gpt_icon":0},{"id":"2489296144","title":"After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2489296144","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489296144?lang=en_us&edition=fundamental","pubTime":"2024-12-05 04:14","pubTimestamp":1733343258,"startTime":"0","endTime":"0","summary":"On Wednesday, Atea Pharmaceuticals, Inc.  released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling andcan lead to serious liver damage.The study met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment .Primary endpoint results demonstrated a 98%  SVR12 rate in the per-protocol treatment adherent patient population after eight weeks of treatment with a regimen of bemnifosbuvir and ruzasvir.Also Read: Atea Pharmaceuticals’ COVID-19 Treatment Flunks In Late-Stage Study, Blames’ Constantly Evolving’ Virus. The efficacy evaluable patient population, which included 17% treatment non-adherent patients, achieved a 95%  SVR12 rate demonstrating the potency and forgiveness of the regimen.In June, Atea Pharmaceuticals shared new data from the lead-in cohort  of its ongoing Phase 2 combination study of bemnifosbuvir and ruzasvir forhepatitis C virus.The regimen was generally saf","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FMsScQo8bQujiB2D8yd.rA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/aea084d777829ea6e71337923d1865b0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FMsScQo8bQujiB2D8yd.rA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/aea084d777829ea6e71337923d1865b0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/failed-covid-19-drug-trial-201418711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BNTX","AVIR","SSI"],"gpt_icon":0},{"id":"2488019334","title":"BUZZ-Atea Pharma rises as combo drug meets main goal in mid-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2488019334","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488019334?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:03","pubTimestamp":1733317437,"startTime":"0","endTime":"0","summary":"BUZZ-Atea Pharma rises as combo drug meets main goal in mid-stage study** Shares of drug developer Atea Pharmaceuticals AVIR.O rise 6.9% to $3.72 premarket ** Co says its drug combination met the main goal for treating Hepatitis C Virus  in a mid-stage study** The combination of bemnifosbuvir and ruzasvir showed 98% success rate in eliminating HCV, co says** Bemnifosbuvir and ruzasvir are both oral antiviral medications to treat HCV ** HCV is a leading cause of chronic liver diseases and liver transplants, affecting around 50 mln people worldwide** As of last close, stock had risen 14.1% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nL3N3N50TN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR","BK4007"],"gpt_icon":0},{"id":"2488676751","title":"Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir","url":"https://stock-news.laohu8.com/highlight/detail?id=2488676751","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488676751?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:06","pubTimestamp":1733314011,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals (AVIR) announced that the Company’s Phase 2 study of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-announces-results-from-phase-2-regimen-of-bemnifosbuvir?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-announces-results-from-phase-2-regimen-of-bemnifosbuvir?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AVIR"],"gpt_icon":0},{"id":"2488519551","title":"Atea Pharmaceuticals Inc: Global Phase 3 Program Initiation Expected Early in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2488519551","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488519551?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:00","pubTimestamp":1733313602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUABWTBX9:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVIR","BK4007"],"gpt_icon":0},{"id":"2488162598","title":"Atea Pharmaceuticals Inc - Phase 2 Study Achieves 98% Svr12 After 8 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2488162598","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488162598?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:00","pubTimestamp":1733313602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUABWTBX9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVIR","BK4007"],"gpt_icon":0},{"id":"2488162515","title":"Atea Pharmaceuticals Inc - No Drug-Related Serious Adverse Events or Treatment Discontinuations","url":"https://stock-news.laohu8.com/highlight/detail?id=2488162515","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488162515?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:00","pubTimestamp":1733313602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUABWTBX9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVIR","BK4007"],"gpt_icon":0},{"id":"2488162366","title":"Atea Pharmaceuticals Announces Positive Results From Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (Hcv)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488162366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488162366?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:00","pubTimestamp":1733313602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUABWTBX9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVIR","BK4007"],"gpt_icon":0},{"id":"2488162331","title":"Atea Pharmaceuticals Inc - Regimen Generally Safe and Well-Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2488162331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488162331?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:00","pubTimestamp":1733313602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUABWTBX9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVIR","BK4007"],"gpt_icon":0},{"id":"2488516252","title":"Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488516252","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488516252?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:00","pubTimestamp":1733313600,"startTime":"0","endTime":"0","summary":"Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment  after Short Eight Week Treatment Duration. Global Phase 3 Program Initiation Expected Early in 2025. In the Phase 2 study, 99%  of treatment adherent patients who were non-cirrhotic and infected with genotypes 1-4 achieved SVR12, demonstrating robust pan-genotypic potency and supporting an eight-week treatment in the Phase 3 program. Treatment adherent patients with cirrhosis achieved a 88%  SVR12 rate. Viral kinetics were slower in these cirrhotic patients, however, all patients achieved 100% end of treatment response. To maximize efficacy, treatment duration in patients with cirrhosis will be 12 weeks in the Phase 3 program. Based on the high proportion of people between 20-49 years old who ar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atea-pharmaceuticals-announces-positive-results-120000112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","AVIR","BK4007","SOF","BK4218","PK"],"gpt_icon":0},{"id":"2486079555","title":"Atea Pharmaceuticals to Present and Provide a Business Update at the 7TH Annual Evercore Healthconx Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486079555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486079555?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:00","pubTimestamp":1732622402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nTUA8PWSZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AVIR"],"gpt_icon":0},{"id":"2486071670","title":"Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486071670","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486071670?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:00","pubTimestamp":1732622400,"startTime":"0","endTime":"0","summary":"BOSTON, Nov.  26, 2024  (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987345/0/en/Atea-Pharmaceuticals-to-Present-and-Provide-a-Business-Update-at-the-7th-Annual-Evercore-HealthCONx-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR","BK4007"],"gpt_icon":0},{"id":"2485229629","title":"Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485229629","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485229629?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:40","pubTimestamp":1732286411,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atea Pharmaceuticals, Inc.  one of those stocks right now?Let's take a closer look at the stock's year-to-date performance to find out.Atea Pharmaceuticals, Inc. is one of 1023 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Atea Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 .Our latest available data shows that AVIR has returned about 6.6% since the start of ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atea-pharmaceuticals-avir-stock-outpacing-144011099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","BFLY","AVIR","BK4007"],"gpt_icon":0},{"id":"2483092783","title":"Atea Pharmaceuticals presents three HCV poster presentations at AASLD","url":"https://stock-news.laohu8.com/highlight/detail?id=2483092783","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483092783?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:05","pubTimestamp":1731686716,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals (AVIR) announced it presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potenti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-presents-three-hcv-poster-presentations-at-aasld?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-presents-three-hcv-poster-presentations-at-aasld?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AVIR"],"gpt_icon":0},{"id":"2483306990","title":"Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at Aasld’s the Liver Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483306990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483306990?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:00","pubTimestamp":1731686400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUAZ1QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AVIR"],"gpt_icon":0},{"id":"2483130645","title":"Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483130645","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483130645?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:00","pubTimestamp":1731686400,"startTime":"0","endTime":"0","summary":"BOSTON, Nov. 15, 2024  -- Atea Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus . The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for the treatment of HCV. These data are being presented at the American Association for the Study of Liver Diseases’  The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.A multiscale HCV viral kinetic model was utilized to estimate the clinical effectiveness of the combination of bemnifosbuvir and ruzasvir in blocking HCV replication and viral assembly/secretion against HCV. This model evaluated the combination of bemnifosbuvir and ruzasvir in the lead-in cohort  of a Phase 2 single-ar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atea-pharmaceuticals-presents-multiple-datasets-160000655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1878469433.USD","BK4181","BK4218","QD","BK4503","BK4563","PK","BK4166","AVIR","BK4139","SOF","BK4007","ALT"],"gpt_icon":0},{"id":"2482794192","title":"Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2482794192","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482794192?lang=en_us&edition=fundamental","pubTime":"2024-11-12 09:01","pubTimestamp":1731373289,"startTime":"0","endTime":"0","summary":"Cash, Cash Equivalents, and Marketable Securities: $482.8 million as of September 30, 2024.R&D Expenses: Decreased in Q3 2024 compared to the prior year, primarily due to lower COVID-19 spending, offset by higher HCV Phase 2 trial spending.G&A Expenses: Decreased in Q3 2024 compared to the corresponding period in 2023, mainly due to lower professional fees.Interest Income: Decreased in Q3 2024 compared to the prior year due to lower investment balances.Cash Runway: Projected to extend well into 2027.GuruFocus has detected 2 Warning Sign with AVIR.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Atea Pharmaceuticals Inc  has executed two large global clinical programs on time and on budget.Q: Will the Phase 3 trial use the same doses as Phase 2, and will there be more US sites involved?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atea-pharmaceuticals-inc-avir-q3-010129856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AVIR"],"gpt_icon":0},{"id":"2482519004","title":"Atea Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482519004","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482519004?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:48","pubTimestamp":1731102497,"startTime":"0","endTime":"0","summary":"* Atea Pharmaceuticals Inc    reported a quarterly adjusted loss of 37 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -40 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Atea Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR"],"gpt_icon":0},{"id":"2481165506","title":"BRIEF-Atea Pharmaceuticals Inc Files For Mixed Shelf Of Up To $500 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2481165506","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481165506?lang=en_us&edition=fundamental","pubTime":"2024-11-08 07:20","pubTimestamp":1731021627,"startTime":"0","endTime":"0","summary":"BRIEF-Atea Pharmaceuticals Inc Files For Mixed Shelf Of Up To $500 Million - SEC FilingNov 7  - Atea Pharmaceuticals Inc AVIR.O:ATEA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $500 MILLION - SEC FILINGSource text: [ID:n0001193125-24-253272]Further company coverage: AVIR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3ME23Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVIR"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":70}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVIR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-06","symbol":"AVIR","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741237200000,"reportTimeType":"post","actualEps":-0.4},{"market":"US","date":"2024-11-07","symbol":"AVIR","fiscalQuarterEnding":"2024/09","expectedEps":-0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.37},{"market":"US","date":"2024-08-07","symbol":"AVIR","fiscalQuarterEnding":"2024/06","expectedEps":-0.77,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2024-05-14","symbol":"AVIR","fiscalQuarterEnding":"2024/03","expectedEps":-0.61,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2024-02-28","symbol":"AVIR","fiscalQuarterEnding":"2023/12","expectedEps":-0.44,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1709096400000,"reportTimeType":"post","actualEps":-0.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVIR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVIR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0,"hold":0.3333,"sell":0.3333,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.3333,"analysts":3,"updateTime":1723521600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVIR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVIR","date":"2025-04-01","current":-1.518664,"percent":0.540132,"low":-466.703742,"twenty":-2.633726,"median":-1.608506,"eighty":27.2705,"high":114.976269,"avg":-9.938296,"sd":78.295168,"marketCap":255720285},"quantilePoints":[{"date":"2020-10-30","current":-171.312553,"twenty":-156.993218,"median":-135.514215,"eighty":-135.514215,"marketCap":2404200368},{"date":"2020-11-06","current":-192.938363,"twenty":-185.270517,"median":-169.618626,"eighty":-144.887281,"marketCap":2707696987},{"date":"2020-11-13","current":-182.492476,"twenty":-179.57892,"median":-166.738948,"eighty":-150.14975,"marketCap":2561099403},{"date":"2020-11-20","current":-187.291937,"twenty":-185.891624,"median":-173.26057,"eighty":-154.847576,"marketCap":2628455050},{"date":"2020-11-27","current":-194.462898,"twenty":-190.555572,"median":-181.814905,"eighty":-159.059809,"marketCap":2729092310},{"date":"2020-12-04","current":-165.157949,"twenty":-189.166551,"median":-180.855012,"eighty":-159.059809,"marketCap":2317826657},{"date":"2020-12-11","current":-67.833477,"twenty":-188.274415,"median":-172.131284,"eighty":-157.207782,"marketCap":2459506214},{"date":"2020-12-18","current":-77.722536,"twenty":-187.969508,"median":-166.738948,"eighty":-135.514215,"marketCap":2818063721},{"date":"2020-12-24","current":-78.565613,"twenty":-187.291937,"median":-160.979594,"eighty":-78.793471,"marketCap":2848631987},{"date":"2020-12-31","current":-95.199284,"twenty":-184.491311,"median":-158.946881,"eighty":-79.413246,"marketCap":3451735627},{"date":"2021-01-08","current":-109.508798,"twenty":-183.384611,"median":-157.817596,"eighty":-81.91969,"marketCap":3970569992},{"date":"2021-01-15","current":-121.767585,"twenty":-182.650576,"median":-148.839779,"eighty":-87.757425,"marketCap":4415049113},{"date":"2021-01-22","current":-123.658811,"twenty":-181.67939,"median":-135.514215,"eighty":-89.411678,"marketCap":4483621170},{"date":"2021-01-29","current":-166.336709,"twenty":-180.96794,"median":-133.570656,"eighty":-92.48321,"marketCap":6031036401},{"date":"2021-02-05","current":-196.09503,"twenty":-183.486247,"median":-135.514215,"eighty":-94.775467,"marketCap":7110013598},{"date":"2021-02-12","current":-186.912332,"twenty":-187.630723,"median":-154.457973,"eighty":-95.135484,"marketCap":6777067342},{"date":"2021-02-19","current":-190.558068,"twenty":-189.772842,"median":-158.862185,"eighty":-95.217512,"marketCap":6909254441},{"date":"2021-02-26","current":-171.71417,"twenty":-189.772842,"median":-159.511523,"eighty":-96.684921,"marketCap":6226012372},{"date":"2021-03-05","current":-136.669532,"twenty":-188.951987,"median":-160.201207,"eighty":-99.647082,"marketCap":4955363881},{"date":"2021-03-12","current":-154.624782,"twenty":-188.240537,"median":-158.890417,"eighty":-101.734266,"marketCap":5606385344},{"date":"2021-03-19","current":-177.934707,"twenty":-187.800115,"median":-159.27838,"eighty":-104.710098,"marketCap":6451556610},{"date":"2021-03-26","current":-137.079677,"twenty":-187.140095,"median":-158.946881,"eighty":-108.114304,"marketCap":4970234929},{"date":"2021-04-01","current":-436.925398,"twenty":-188.274415,"median":-159.045237,"eighty":-110.534161,"marketCap":4783022327},{"date":"2021-04-09","current":-427.100056,"twenty":-190.548954,"median":-160.935243,"eighty":-115.451347,"marketCap":4675464309},{"date":"2021-04-16","current":-339.654512,"twenty":-191.931363,"median":-165.157949,"eighty":-119.324942,"marketCap":3718197948},{"date":"2021-04-23","current":-275.185154,"twenty":-195.768604,"median":-167.331823,"eighty":-122.091144,"marketCap":3012451876},{"date":"2021-04-30","current":-186.757076,"twenty":-199.196041,"median":-171.312553,"eighty":-123.440067,"marketCap":2044429713},{"date":"2021-05-07","current":-161.135608,"twenty":-197.99537,"median":-168.007959,"eighty":-124.055285,"marketCap":1763951496},{"date":"2021-05-14","current":79.797223,"twenty":-196.113259,"median":-166.426176,"eighty":-123.440067,"marketCap":1895503226},{"date":"2021-05-21","current":78.125347,"twenty":-195.768604,"median":-164.402964,"eighty":-110.534161,"marketCap":1855789496},{"date":"2021-05-28","current":71.124369,"twenty":-194.157991,"median":-160.979594,"eighty":-99.246051,"marketCap":1689488253},{"date":"2021-06-04","current":74.990581,"twenty":-192.938363,"median":-159.511523,"eighty":-95.039783,"marketCap":1781326253},{"date":"2021-06-11","current":82.757835,"twenty":-192.37372,"median":-159.183468,"eighty":-82.507565,"marketCap":1965829623},{"date":"2021-06-18","current":81.469098,"twenty":-191.978471,"median":-158.890417,"eighty":-77.722536,"marketCap":1935216956},{"date":"2021-06-25","current":82.931989,"twenty":-191.742933,"median":-157.410556,"eighty":-69.975347,"marketCap":1969966469},{"date":"2021-07-02","current":81.08596,"twenty":-190.990999,"median":-154.624782,"eighty":67.989602,"marketCap":1926115893},{"date":"2021-07-09","current":80.075869,"twenty":-190.877549,"median":-153.804491,"eighty":71.451777,"marketCap":1902122181},{"date":"2021-07-16","current":79.762392,"twenty":-190.616292,"median":-149.016908,"eighty":72.482768,"marketCap":1894675857},{"date":"2021-07-23","current":87.459985,"twenty":-190.521611,"median":-146.01173,"eighty":76.523133,"marketCap":2077524488},{"date":"2021-07-30","current":87.21617,"twenty":-190.129695,"median":-138.834187,"eighty":78.278602,"marketCap":2071732902},{"date":"2021-08-06","current":108.532582,"twenty":-189.511691,"median":-136.601174,"eighty":79.811155,"marketCap":2578082956},{"date":"2021-08-13","current":64.910668,"twenty":-188.522858,"median":-135.134867,"eighty":80.20126,"marketCap":2290437846},{"date":"2021-08-20","current":69.578982,"twenty":-188.17278,"median":-133.639014,"eighty":79.908681,"marketCap":2455163951},{"date":"2021-08-27","current":73.543529,"twenty":-187.46133,"median":-129.708455,"eighty":79.811155,"marketCap":2595056974},{"date":"2021-09-03","current":67.819567,"twenty":-186.988253,"median":-125.64118,"eighty":79.769358,"marketCap":2393081248},{"date":"2021-09-10","current":67.092343,"twenty":-186.819178,"median":-123.385381,"eighty":79.6579,"marketCap":2367420398},{"date":"2021-09-17","current":61.532592,"twenty":-186.754529,"median":-116.674948,"eighty":79.170269,"marketCap":2171239057},{"date":"2021-09-24","current":75.396779,"twenty":-185.83684,"median":-107.184641,"eighty":78.431857,"marketCap":2660450755},{"date":"2021-10-01","current":98.550675,"twenty":-184.365164,"median":-99.847598,"eighty":79.353564,"marketCap":3477459123},{"date":"2021-10-08","current":93.976197,"twenty":-183.486247,"median":-95.199284,"eighty":79.950478,"marketCap":3316044096},{"date":"2021-10-15","current":92.146406,"twenty":-182.808676,"median":-92.009265,"eighty":81.232249,"marketCap":3251478085},{"date":"2021-10-22","current":29.86313,"twenty":-182.369073,"median":-82.507565,"eighty":81.232249,"marketCap":1053750408},{"date":"2021-10-29","current":27.306114,"twenty":-181.597122,"median":-78.679542,"eighty":81.099892,"marketCap":963523546},{"date":"2021-11-05","current":25.359029,"twenty":-180.96794,"median":-70.955139,"eighty":80.856077,"marketCap":894818688},{"date":"2021-11-12","current":38.198876,"twenty":-179.102829,"median":-70.055098,"eighty":80.32665,"marketCap":944047012},{"date":"2021-11-19","current":27.2705,"twenty":-177.005044,"median":-64.575101,"eighty":79.950478,"marketCap":673963140},{"date":"2021-11-26","current":27.371377,"twenty":-176.330583,"median":25.218276,"eighty":79.83902,"marketCap":676456222},{"date":"2021-12-03","current":27.102371,"twenty":-176.111839,"median":25.704021,"eighty":79.783291,"marketCap":669808003},{"date":"2021-12-10","current":26.799739,"twenty":-175.627494,"median":26.093598,"eighty":79.69273,"marketCap":662328758},{"date":"2021-12-17","current":28.750034,"twenty":-174.603768,"median":26.564359,"eighty":79.431789,"marketCap":710528341},{"date":"2021-12-23","current":30.633077,"twenty":-173.693594,"median":26.850178,"eighty":79.136017,"marketCap":757065870},{"date":"2021-12-31","current":30.061439,"twenty":-173.535454,"median":27.03512,"eighty":78.738368,"marketCap":742938406},{"date":"2022-01-07","current":25.690089,"twenty":-172.807662,"median":27.068745,"eighty":77.999956,"marketCap":634904857},{"date":"2022-01-14","current":24.546813,"twenty":-172.137986,"median":26.900617,"eighty":77.393902,"marketCap":606649929},{"date":"2022-01-21","current":21.654996,"twenty":-171.736956,"median":26.766114,"eighty":76.975933,"marketCap":535181581},{"date":"2022-01-28","current":22.865524,"twenty":-171.71417,"median":26.328978,"eighty":76.662456,"marketCap":565098564},{"date":"2022-02-04","current":23.000027,"twenty":-171.312553,"median":26.093598,"eighty":76.488302,"marketCap":568422673},{"date":"2022-02-11","current":22.66377,"twenty":-168.09122,"median":25.807779,"eighty":75.396779,"marketCap":560112400},{"date":"2022-02-18","current":19.906456,"twenty":-167.924698,"median":25.690089,"eighty":75.396779,"marketCap":491968161},{"date":"2022-02-25","current":21.419616,"twenty":-166.976098,"median":25.359029,"eighty":75.378012,"marketCap":529364390},{"date":"2022-03-04","current":3.948735,"twenty":-166.48873,"median":24.788709,"eighty":75.073047,"marketCap":478547148},{"date":"2022-03-11","current":3.976204,"twenty":-166.354602,"median":24.479561,"eighty":74.992061,"marketCap":481876171},{"date":"2022-03-18","current":4.862094,"twenty":-165.393701,"median":23.807046,"eighty":74.851258,"marketCap":589237184},{"date":"2022-03-25","current":4.745349,"twenty":-163.949973,"median":23.269033,"eighty":74.398458,"marketCap":575088833},{"date":"2022-04-01","current":4.875829,"twenty":-161.638082,"median":23.117718,"eighty":74.106492,"marketCap":590901696},{"date":"2022-04-08","current":4.573665,"twenty":-161.010797,"median":23.000027,"eighty":73.646748,"marketCap":554282436},{"date":"2022-04-14","current":4.525593,"twenty":-160.926372,"median":22.865524,"eighty":73.205722,"marketCap":548456644},{"date":"2022-04-22","current":4.044878,"twenty":-160.06327,"median":22.058506,"eighty":72.410188,"marketCap":490198730},{"date":"2022-04-29","current":4.032693,"twenty":-159.488323,"median":21.654996,"eighty":71.812079,"marketCap":488722059},{"date":"2022-05-06","current":3.792243,"twenty":-159.382162,"median":21.503681,"eighty":71.654826,"marketCap":459581902},{"date":"2022-05-13","current":12.540245,"twenty":-159.155821,"median":20.915229,"eighty":71.605033,"marketCap":606947838},{"date":"2022-05-20","current":12.884284,"twenty":-158.986223,"median":20.141837,"eighty":71.560583,"marketCap":623599356},{"date":"2022-05-27","current":14.071221,"twenty":-158.913003,"median":19.502947,"eighty":71.524315,"marketCap":681047094},{"date":"2022-06-03","current":13.417546,"twenty":-158.867831,"median":13.555162,"eighty":71.479642,"marketCap":649409209},{"date":"2022-06-10","current":13.27993,"twenty":-158.508321,"median":13.709979,"eighty":71.312455,"marketCap":642748602},{"date":"2022-06-17","current":11.181288,"twenty":-157.53242,"median":13.53796,"eighty":70.650671,"marketCap":541174341},{"date":"2022-06-24","current":12.265013,"twenty":-156.71581,"median":13.27993,"eighty":69.928889,"marketCap":593626623},{"date":"2022-07-01","current":12.557447,"twenty":-156.024233,"median":12.93589,"eighty":69.874563,"marketCap":607780414},{"date":"2022-07-08","current":13.606767,"twenty":-154.624782,"median":12.93589,"eighty":69.837029,"marketCap":658567544},{"date":"2022-07-15","current":13.933605,"twenty":-154.533639,"median":13.27993,"eighty":69.719735,"marketCap":674386487},{"date":"2022-07-22","current":13.761585,"twenty":-153.804491,"median":13.443349,"eighty":69.602441,"marketCap":666060728},{"date":"2022-07-29","current":14.105625,"twenty":-152.114706,"median":13.555162,"eighty":69.578982,"marketCap":682712246},{"date":"2022-08-05","current":15.120542,"twenty":-149.194038,"median":13.675575,"eighty":69.156722,"marketCap":731834224},{"date":"2022-08-12","current":45.098857,"twenty":-148.839779,"median":13.813191,"eighty":68.570251,"marketCap":700204851},{"date":"2022-08-19","current":44.187227,"twenty":-148.362663,"median":13.881999,"eighty":68.523333,"marketCap":686050888},{"date":"2022-08-26","current":41.988591,"twenty":-146.01173,"median":13.933605,"eighty":68.030697,"marketCap":651914861},{"date":"2022-09-02","current":39.95083,"twenty":-143.642002,"median":14.019615,"eighty":67.989602,"marketCap":620276592},{"date":"2022-09-09","current":42.256717,"twenty":-141.199359,"median":14.06262,"eighty":67.909876,"marketCap":656077791},{"date":"2022-09-16","current":35.98256,"twenty":-137.781481,"median":14.088423,"eighty":67.833642,"marketCap":558665226},{"date":"2022-09-23","current":31.10266,"twenty":-136.751561,"median":14.217438,"eighty":67.500527,"marketCap":482899897},{"date":"2022-09-30","current":30.512782,"twenty":-136.614846,"median":14.535674,"eighty":67.27063,"marketCap":473741451},{"date":"2022-10-07","current":28.957649,"twenty":-135.731607,"median":14.862512,"eighty":67.176794,"marketCap":449596456},{"date":"2022-10-14","current":28.15327,"twenty":-135.514215,"median":19.872831,"eighty":67.106418,"marketCap":437107665},{"date":"2022-10-21","current":28.528647,"twenty":-134.907259,"median":20.562159,"eighty":66.974213,"marketCap":442935767},{"date":"2022-10-28","current":31.638913,"twenty":-134.153974,"median":21.38599,"eighty":66.781304,"marketCap":491225757},{"date":"2022-11-04","current":32.389666,"twenty":-133.711929,"median":21.604558,"eighty":65.670736,"marketCap":502881962},{"date":"2022-11-11","current":12.077105,"twenty":-132.636436,"median":21.38599,"eighty":65.403305,"marketCap":430597093},{"date":"2022-11-18","current":10.909106,"twenty":-131.930075,"median":20.562159,"eighty":65.103031,"marketCap":388953274},{"date":"2022-11-25","current":10.955826,"twenty":-129.286916,"median":19.889643,"eighty":64.999812,"marketCap":390619026},{"date":"2022-12-02","current":11.212786,"twenty":-126.766801,"median":15.120542,"eighty":64.938819,"marketCap":399780667},{"date":"2022-12-09","current":10.255027,"twenty":-125.869038,"median":14.552876,"eighty":64.150601,"marketCap":365632735},{"date":"2022-12-16","current":10.768946,"twenty":-124.451759,"median":14.260443,"eighty":62.377111,"marketCap":383956015},{"date":"2022-12-23","current":10.722226,"twenty":-123.494753,"median":14.097024,"eighty":61.180709,"marketCap":382290263},{"date":"2022-12-30","current":11.236146,"twenty":-122.738263,"median":14.071221,"eighty":55.100568,"marketCap":400613543},{"date":"2023-01-06","current":10.979186,"twenty":-121.156924,"median":14.045418,"eighty":46.278613,"marketCap":391451903},{"date":"2023-01-13","current":11.516465,"twenty":-117.898548,"median":13.950807,"eighty":46.053387,"marketCap":410608060},{"date":"2023-01-20","current":11.446386,"twenty":-114.635614,"median":13.899201,"eighty":46.010486,"marketCap":408109431},{"date":"2023-01-27","current":10.745586,"twenty":-109.508798,"median":13.856196,"eighty":45.903236,"marketCap":383123139},{"date":"2023-02-03","current":10.535347,"twenty":-107.184641,"median":13.761585,"eighty":45.474234,"marketCap":375627251},{"date":"2023-02-10","current":9.834548,"twenty":-103.060402,"median":13.659535,"eighty":45.098857,"marketCap":350640960},{"date":"2023-02-17","current":9.927987,"twenty":-100.850175,"median":13.555162,"eighty":44.937981,"marketCap":353972465},{"date":"2023-02-24","current":8.573109,"twenty":-99.246051,"median":13.469152,"eighty":44.466079,"marketCap":305665635},{"date":"2023-03-03","current":-2.538161,"twenty":-95.964888,"median":13.331536,"eighty":44.219402,"marketCap":294195756},{"date":"2023-03-10","current":-2.401547,"twenty":-95.208398,"median":12.953092,"eighty":44.144327,"marketCap":278360857},{"date":"2023-03-17","current":-2.710728,"twenty":-95.071683,"median":12.884284,"eighty":43.9191,"marketCap":314197733},{"date":"2023-03-24","current":-2.157078,"twenty":-94.511151,"median":12.695062,"eighty":43.736775,"marketCap":250024722},{"date":"2023-03-31","current":-2.408737,"twenty":-90.587427,"median":12.600452,"eighty":43.532999,"marketCap":279194272},{"date":"2023-04-05","current":-2.415927,"twenty":-89.411678,"median":12.557447,"eighty":43.425749,"marketCap":280027688},{"date":"2023-04-14","current":-2.423117,"twenty":-86.44496,"median":12.505841,"eighty":43.221972,"marketCap":280861104},{"date":"2023-04-21","current":-2.344024,"twenty":-81.331815,"median":12.282215,"eighty":42.953846,"marketCap":271693531},{"date":"2023-04-28","current":-2.379976,"twenty":-79.258302,"median":12.230609,"eighty":42.578469,"marketCap":275860609},{"date":"2023-05-05","current":-2.396017,"twenty":-78.702328,"median":12.100465,"eighty":42.149467,"marketCap":277719925},{"date":"2023-05-12","current":-2.525658,"twenty":-78.228382,"median":11.92588,"eighty":41.83844,"marketCap":276051937},{"date":"2023-05-19","current":-2.739309,"twenty":-75.015577,"median":11.731751,"eighty":41.570314,"marketCap":299403763},{"date":"2023-05-26","current":-3.53287,"twenty":-70.863995,"median":11.512296,"eighty":41.205661,"marketCap":386139115},{"date":"2023-06-02","current":-3.113198,"twenty":-70.608794,"median":11.483414,"eighty":40.647959,"marketCap":340269458},{"date":"2023-06-09","current":-3.258176,"twenty":-70.102948,"median":11.446386,"eighty":40.186782,"marketCap":356115339},{"date":"2023-06-16","current":-3.166611,"twenty":-69.546973,"median":11.318087,"eighty":40.036631,"marketCap":346107414},{"date":"2023-06-23","current":-2.983482,"twenty":-67.833477,"median":11.259506,"eighty":39.95083,"marketCap":326091564},{"date":"2023-06-30","current":-2.861395,"twenty":-65.226776,"median":11.224466,"eighty":39.95083,"marketCap":312747663},{"date":"2023-07-07","current":-2.75457,"twenty":-28.146626,"median":11.197037,"eighty":39.182114,"marketCap":301071750},{"date":"2023-07-14","current":-2.861395,"twenty":-3.801459,"median":11.166066,"eighty":38.537448,"marketCap":312747663},{"date":"2023-07-21","current":-2.807983,"twenty":-3.706843,"median":11.072626,"eighty":38.299055,"marketCap":306909707},{"date":"2023-07-28","current":-2.540919,"twenty":-3.6107,"median":11.002546,"eighty":38.198876,"marketCap":277719925},{"date":"2023-08-04","current":-2.640114,"twenty":-3.548131,"median":10.967506,"eighty":37.383889,"marketCap":288561844},{"date":"2023-08-11","current":-2.663513,"twenty":-3.496244,"median":10.955826,"eighty":36.776214,"marketCap":282723888},{"date":"2023-08-18","current":-2.67137,"twenty":-3.448936,"median":10.920786,"eighty":36.282862,"marketCap":283557881},{"date":"2023-08-25","current":-2.639942,"twenty":-3.383314,"median":10.909106,"eighty":35.775559,"marketCap":280221906},{"date":"2023-09-01","current":-2.639942,"twenty":-3.29938,"median":10.885746,"eighty":34.557553,"marketCap":280221906},{"date":"2023-09-08","current":-2.577086,"twenty":-3.262754,"median":10.803986,"eighty":33.730299,"marketCap":273549956},{"date":"2023-09-15","current":-2.577086,"twenty":-3.258176,"median":10.768946,"eighty":33.569423,"marketCap":273549956},{"date":"2023-09-21","current":-2.498516,"twenty":-3.22155,"median":10.768946,"eighty":33.151146,"marketCap":265210018},{"date":"2023-10-06","current":-2.364948,"twenty":-3.197133,"median":10.768946,"eighty":32.872294,"marketCap":251032124},{"date":"2023-10-09","current":-2.33352,"twenty":-3.191029,"median":10.768946,"eighty":32.797219,"marketCap":247696149},{"date":"2023-10-17","current":-2.357091,"twenty":-3.184924,"median":10.757266,"eighty":32.722143,"marketCap":250198131},{"date":"2023-11-01","current":-2.553515,"twenty":-3.172715,"median":10.733906,"eighty":32.571992,"marketCap":271047975},{"date":"2023-11-10","current":-1.900308,"twenty":-3.162033,"median":10.710546,"eighty":32.464742,"marketCap":249364137},{"date":"2023-11-17","current":-1.850265,"twenty":-3.149824,"median":10.675507,"eighty":32.429404,"marketCap":242797342},{"date":"2023-11-24","current":-1.812115,"twenty":-3.14372,"median":10.628787,"eighty":32.407954,"marketCap":237791212},{"date":"2023-12-01","current":-1.901132,"twenty":-3.140668,"median":10.582067,"eighty":32.303866,"marketCap":249472183},{"date":"2023-12-08","current":-1.86934,"twenty":-3.129985,"median":10.535347,"eighty":32.153715,"marketCap":245300408},{"date":"2023-12-15","current":-1.894773,"twenty":-3.117777,"median":10.42211,"eighty":31.956565,"marketCap":248637828},{"date":"2023-12-22","current":-1.996506,"twenty":-3.10099,"median":10.266707,"eighty":31.681026,"marketCap":261987510},{"date":"2023-12-29","current":-1.971073,"twenty":-3.082677,"median":10.255027,"eighty":31.638913,"marketCap":258650090},{"date":"2024-01-05","current":-1.971073,"twenty":-3.064364,"median":10.231667,"eighty":31.638913,"marketCap":258650090},{"date":"2024-01-12","current":-2.276271,"twenty":-3.047577,"median":10.184947,"eighty":31.478037,"marketCap":298699136},{"date":"2024-01-19","current":-2.269913,"twenty":-3.035369,"median":10.004174,"eighty":31.263536,"marketCap":297864781},{"date":"2024-01-26","current":-2.397079,"twenty":-3.006373,"median":9.834548,"eighty":31.085409,"marketCap":314551884},{"date":"2024-02-02","current":-2.683202,"twenty":-2.946856,"median":9.577588,"eighty":31.055333,"marketCap":352097864},{"date":"2024-02-09","current":-2.708636,"twenty":-2.891917,"median":9.390708,"eighty":30.990254,"marketCap":355435285},{"date":"2024-02-16","current":-2.676844,"twenty":-2.888865,"median":8.806709,"eighty":30.896513,"marketCap":351263509},{"date":"2024-02-23","current":-2.562395,"twenty":-2.882761,"median":6.674963,"eighty":30.855984,"marketCap":336245117},{"date":"2024-03-01","current":-2.668137,"twenty":-2.882761,"median":4.999441,"eighty":30.721892,"marketCap":362749188},{"date":"2024-03-08","current":-2.525754,"twenty":-2.873604,"median":4.937635,"eighty":30.686879,"marketCap":343391343},{"date":"2024-03-15","current":-2.38337,"twenty":-2.861395,"median":4.862094,"eighty":30.626352,"marketCap":324033498},{"date":"2024-03-22","current":-2.538135,"twenty":-2.859869,"median":4.779686,"eighty":30.582117,"marketCap":345074634},{"date":"2024-03-28","current":-2.476229,"twenty":-2.853765,"median":4.714446,"eighty":30.512782,"marketCap":336658180},{"date":"2024-04-05","current":-2.38337,"twenty":-2.838504,"median":4.601134,"eighty":30.431323,"marketCap":324033498},{"date":"2024-04-12","current":-2.38337,"twenty":-2.823244,"median":4.553063,"eighty":30.405531,"marketCap":324033498},{"date":"2024-04-19","current":-2.290512,"twenty":-2.823244,"median":4.525593,"eighty":30.351906,"marketCap":311408816},{"date":"2024-04-26","current":-2.284321,"twenty":-2.815613,"median":4.46722,"eighty":30.08378,"marketCap":310567171},{"date":"2024-05-03","current":-2.372639,"twenty":-2.815613,"median":4.353909,"eighty":30.061439,"marketCap":322574473},{"date":"2024-05-10","current":-2.434588,"twenty":-2.807983,"median":4.312705,"eighty":30.030154,"marketCap":330996783},{"date":"2024-05-17","current":-1.904126,"twenty":-2.800352,"median":4.257766,"eighty":29.976529,"marketCap":311625470},{"date":"2024-05-24","current":-1.89898,"twenty":-2.792722,"median":4.22424,"eighty":29.910048,"marketCap":310783239},{"date":"2024-05-31","current":-1.85781,"twenty":-2.783638,"median":4.207069,"eighty":29.872514,"marketCap":304045391},{"date":"2024-06-07","current":-1.955589,"twenty":-2.778242,"median":4.154756,"eighty":29.844363,"marketCap":320047780},{"date":"2024-06-14","current":-1.904126,"twenty":-2.777461,"median":4.051745,"eighty":29.76091,"marketCap":311625470},{"date":"2024-06-21","current":-1.76003,"twenty":-2.777461,"median":4.044878,"eighty":29.688214,"marketCap":288043002},{"date":"2024-06-28","current":-1.739445,"twenty":-2.777461,"median":4.032693,"eighty":29.668025,"marketCap":284674078},{"date":"2024-07-05","current":-1.687982,"twenty":-2.777461,"median":3.976204,"eighty":29.559513,"marketCap":276251768},{"date":"2024-07-12","current":-1.734299,"twenty":-2.763867,"median":3.884237,"eighty":29.461726,"marketCap":283831847},{"date":"2024-07-15","current":-1.765176,"twenty":-2.759336,"median":3.860943,"eighty":29.451001,"marketCap":288885233},{"date":"2024-08-02","current":-1.868102,"twenty":-2.754805,"median":3.826593,"eighty":29.440276,"marketCap":305729853},{"date":"2024-08-09","current":-1.678875,"twenty":-2.75457,"median":3.661713,"eighty":29.440276,"marketCap":295477000},{"date":"2024-08-16","current":-1.793998,"twenty":-2.753144,"median":-1.61172,"eighty":29.220795,"marketCap":315738280},{"date":"2024-08-23","current":-1.813185,"twenty":-2.746785,"median":-1.641665,"eighty":29.220795,"marketCap":319115160},{"date":"2024-08-30","current":-1.813185,"twenty":-2.742082,"median":-1.683428,"eighty":29.17215,"marketCap":319115160},{"date":"2024-09-06","current":-1.736437,"twenty":-2.739864,"median":-1.687982,"eighty":29.086853,"marketCap":305607640},{"date":"2024-09-13","current":-1.760421,"twenty":-2.724943,"median":-1.693128,"eighty":29.001437,"marketCap":309828740},{"date":"2024-09-20","current":-1.832372,"twenty":-2.712853,"median":-1.726843,"eighty":28.985414,"marketCap":322492040},{"date":"2024-09-27","current":-1.650094,"twenty":-2.709176,"median":-1.703421,"eighty":28.963202,"marketCap":290411680},{"date":"2024-10-04","current":-1.59733,"twenty":-2.708666,"median":-1.687982,"eighty":28.871848,"marketCap":281125260},{"date":"2024-10-11","current":-1.602127,"twenty":-2.708636,"median":-1.687982,"eighty":28.797008,"marketCap":281969480},{"date":"2024-10-18","current":-1.789201,"twenty":-2.688289,"median":-1.687982,"eighty":28.756759,"marketCap":314894060},{"date":"2024-10-25","current":-1.621314,"twenty":-2.682118,"median":-1.687982,"eighty":28.750034,"marketCap":285346360},{"date":"2024-10-31","current":-1.573346,"twenty":-2.680275,"median":-1.687982,"eighty":28.629674,"marketCap":276904160},{"date":"2024-11-08","current":-1.668975,"twenty":-2.679227,"median":-1.678875,"eighty":28.536962,"marketCap":290411680},{"date":"2024-11-15","current":-1.606684,"twenty":-2.677797,"median":-1.672543,"eighty":28.464296,"marketCap":279572725},{"date":"2024-11-22","current":-1.57756,"twenty":-2.676844,"median":-1.669129,"eighty":28.421396,"marketCap":274504941},{"date":"2024-11-29","current":-1.660079,"twenty":-2.674654,"median":-1.659884,"eighty":28.357046,"marketCap":288863661},{"date":"2024-12-06","current":-1.422231,"twenty":-2.671016,"median":-1.660079,"eighty":28.23907,"marketCap":247476762},{"date":"2024-12-13","current":-1.431939,"twenty":-2.669546,"median":-1.652631,"eighty":28.185445,"marketCap":249166024},{"date":"2024-12-20","current":-1.519312,"twenty":-2.666287,"median":-1.650094,"eighty":28.152215,"marketCap":264369374},{"date":"2024-12-27","current":-1.596976,"twenty":-2.661942,"median":-1.641665,"eighty":28.145941,"marketCap":277883464},{"date":"2025-01-03","current":-1.660079,"twenty":-2.655656,"median":-1.640501,"eighty":28.127174,"marketCap":288863661},{"date":"2025-01-10","current":-1.621246,"twenty":-2.655656,"median":-1.640501,"eighty":28.070873,"marketCap":282106617},{"date":"2025-01-17","current":-1.616392,"twenty":-2.649327,"median":-1.635704,"eighty":27.992672,"marketCap":281261986},{"date":"2025-01-24","current":-1.50475,"twenty":-2.646707,"median":-1.633539,"eighty":27.93629,"marketCap":261835482},{"date":"2025-01-31","current":-1.451355,"twenty":-2.645438,"median":-1.630955,"eighty":27.830492,"marketCap":252544546},{"date":"2025-02-07","current":-1.50475,"twenty":-2.64209,"median":-1.626106,"eighty":27.755914,"marketCap":261835482},{"date":"2025-02-14","current":-1.509604,"twenty":-2.640114,"median":-1.621314,"eighty":27.677227,"marketCap":262680113},{"date":"2025-02-21","current":-1.524166,"twenty":-2.640045,"median":-1.616517,"eighty":27.578237,"marketCap":265214005},{"date":"2025-02-28","current":-1.485334,"twenty":-2.639942,"median":-1.616392,"eighty":27.458272,"marketCap":258456960},{"date":"2025-03-07","current":-1.523743,"twenty":-2.639942,"median":-1.616392,"eighty":27.391553,"marketCap":256575537},{"date":"2025-03-14","current":-1.554218,"twenty":-2.639942,"median":-1.609231,"eighty":27.345272,"marketCap":261707047},{"date":"2025-03-21","current":-1.599931,"twenty":-2.639443,"median":-1.606923,"eighty":27.291868,"marketCap":269404313},{"date":"2025-03-28","current":-1.533902,"twenty":-2.63621,"median":-1.610089,"eighty":27.2705,"marketCap":258286040},{"date":"2025-04-01","current":-1.518664,"twenty":-2.633726,"median":-1.608506,"eighty":27.2705,"marketCap":255720285}],"updateTime":1743660583689}}}